KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Non-Current Debt (2018 - 2026)

Twist Bioscience has reported Non-Current Debt over the past 6 years, most recently at $15.0 million for Q1 2026.

  • Quarterly Non-Current Debt changed 0.0% to $15.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $15.0 million for FY2025, N/A changed from the prior year.
  • Non-Current Debt was $15.0 million for Q1 2026 at Twist Bioscience, roughly flat from $15.0 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $15.0 million in Q4 2024 and troughed at $15.0 million in Q4 2024.
  • The 3-year median for Non-Current Debt is $15.0 million (2024), against an average of $15.0 million.
  • The largest YoY upside for Non-Current Debt was 0.0% in 2025 against a maximum downside of 0.0% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $15.0 million in 2024, then changed by 0.0% to $15.0 million in 2025, then changed by 0.0% to $15.0 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Non-Current Debt are $15.0 million (Q1 2026), $15.0 million (Q4 2025), and $15.0 million (Q3 2025).